Former Orthofix vice president of sales Thomas Guerrieri pleads guilty to federal charges that he helped run a scheme to pay doctors to use Orthofix's bone-growth stimulators; also, Guidant whistleblower asks court to re-open off-label stent case; and 200 Irish plaintiffs join DePuy lawsuit spree.

A former vice president of sales for Orthofix (NSDQ:OFIX) faces up to 5 years in prison after pleading guilty to federal charges that he helped run a scheme to pay doctors to use the company's Spinal-Stim and Cervical-Stim bone growth stimulators.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...